Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities

Novonesis完成对MicroBioGen的收购，强化其酵母技术能力

The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across industries.

此次收购带来了先进的酵母育种专业知识，其在生物乙醇领域拥有经证实的良好业绩记录，并在更广泛的行业应用中展现出巨大潜力。

COPENHAGEN, Denmark, October 1 –

丹麦哥本哈根，10月1日 –

Novonesis today announced the completion of its acquisition of MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications and a proven track record in bioethanol. All regulatory approvals have been obtained, and the transaction has closed..

Novonesis 今日宣布完成对澳大利亚生物技术公司 MicroBioGen 的收购。MicroBioGen 在用于工业应用的酵母菌株方面拥有领先的科学专业知识，并在生物乙醇领域拥有经证实的良好业绩记录。所有监管批准均已获得，交易已正式完成。

The acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further strengthening a collaboration that has spanned more than a decade.

此次收购建立在 Novonesis 于 2013 年对 MicroBioGen 的投资及其现有 23% 持股基础之上，进一步强化了双方长达十余年的合作关系。

“With this acquisition, we strengthen our yeast and R&D expertise and take another step toward delivering on our 2030 strategy. We are pleased to welcome our new colleagues to Novonesis and bring these capabilities into our company, where we can unlock its broader potential. The acquisition reflects our disciplined approach to investing for growth,” says Ester Baiget, CEO of Novonesis..

“通过此次收购，我们强化了酵母和研发领域的专业能力，并在推进2030战略方面迈出了新的一步。我们很高兴欢迎新同事加入Novonesis，将这些能力融入我们的公司，以释放其更广泛的潜力。此次收购体现了我们为增长而投资的审慎策略。”Novonesis首席执行官Ester Baiget表示。

As a pure-play biology company, Novonesis draws on deep expertise in microbiology and industrial fermentation. MicroBioGen’s advanced yeast-breeding capabilities complement this scientific foundation, creating opportunities to develop new biosolutions for customers across multiple industries.

作为一家纯生物科技公司，Novonesis 凭借其在微生物学和工业发酵领域的深厚专业知识。MicroBioGen 先进的酵母育种能力与这一科学基础相得益彰，为开发面向多个行业客户的新生物解决方案创造了机遇。

“MicroBioGen has been a highly valued partner for more than a decade, and today marks the next step in that journey. By bringing together our complementary expertise and technologies, we can further strengthen our yeast capabilities and continue developing the biosolutions our customers need. We see potential for applications not only in bioethanol but also across other industries we serve, as is the case with many of our technologies,” says Claus Crone Fuglsang, Chief Scientific Officer at Novonesis..

“MicroBioGen 在十多年间一直是我们高度重视的合作伙伴，而今天标志着这一合作历程迈出了下一步。通过整合我们互补的专业知识与技术，我们能够进一步强化我们的酵母技术能力，并持续开发客户所需的生物解决方案。正如我们的许多技术一样，我们看到其应用潜力不仅限于生物乙醇领域，还延伸到我们服务的其他行业。”诺维尼斯（Novonesis）首席科学官克劳斯·克罗内·富格斯朗（Claus Crone Fuglsang）表示。

Novonesis will continue to support MicroBioGen's existing partners and ensure continuity in its collaborations.

Novonesis将继续支持MicroBioGen的现有合作伙伴，并确保其合作的连续性。

Get in touch

联系我们

Media relations

媒体关系

Benjamin Hjorth

本杰明·约尔特

Senior Press Manager

高级媒体经理

media-relations@novonesis.com

media-relations@novonesis.com

+45 30 77 13 12

+45 30 77 13 12